CONTROL BIONICS LIMITED (CBL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CBL - CONTROL BIONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Technology Hardware & Equipment
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.18

29 Sep
2022

0.000

OPEN

$0.18

0.000

HIGH

$0.18

0

LOW

$0.18

TARGET
$0.85 372.2% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 .
FNARENA'S MARKET CONSENSUS FORECASTS
CBL: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx - 7.2 - 5.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 2019202020212022
EPS Basic xxxxxxxxx-7.2
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx4.5 M
Book Value Per Share xxxxxxxxx13.7
Net Operating Cash Flow xxxxxxxxx-6.9 M
Net Profit Margin xxxxxxxxx-136.30 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2019202020212022
Return on Capital Employed xxxxxxxxx-41.95 %
Return on Invested Capital xxxxxxxxx-41.77 %
Return on Assets xxxxxxxxx-38.39 %
Return on Equity xxxxxxxxx-41.95 %
Return on Total Capital xxxxxxxxx-44.08 %
Free Cash Flow ex dividends xxxxxxxxx-7.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

26/08/2022

1

Speculative Buy

$0.85

372.22%

Morgans makes only minor forecast changes following pre-released FY22 results for Control Bionics, and retains its Speculative Buy rating, while the target eases to $0.85 from $0.89.

After appointing local distributors, management expects FY23 sales growth in Asia. 

The broker believes covid delays are largely over and the sales pipeline is ready to be converted.

FORECAST
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -5.60 cents.
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -4.10 cents.

CBL STOCK CHART